# EDGAR Filing Document

**Accession Number:** 0000883975
**File Stem:** 0001493152-25-025069
**Filing Date:** 2025-11
**Character Count:** 12991
**Document Hash:** af4a300cc444463941feb02ae0cec47e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-025069.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001493152-25-025069

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251126

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Microbot Medical Inc.
- **CENTRAL INDEX KEY:** 0000883975
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943078125
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19871
- **FILM NUMBER:** 251524336

**BUSINESS ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043
- **BUSINESS PHONE:** 908-938-5561

**MAIL ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STEMCELLS INC
- **DATE OF NAME CHANGE:** 20000524

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTOTHERAPEUTICS INC/DE
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 26, 2025**

**MICROBOT MEDICAL INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-19871** | **94-3078125** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**175 Derby St., Bld. 27**

**Hingham, MA 02043**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (781) 875-3605**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | MBOT | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On November 26, 2025, Microbot Medical Inc. (the "Company") issued a press release announcing that Atlanta-based Emory University Hospital has become the first hospital in the world to adopt the Company's LIBERTY<sup>®</sup> Endovascular Robotic System for patient care. Additionally, the Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

**Item 8.01 Other Events.**

Emory University Hospital has become the first hospital in the world to adopt the Company's LIBERTY<sup>®</sup> Endovascular Robotic System for patient care. Additionally, the Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.

***Forward Looking Statements***

 ****

This Item 8.01 of this Current Report on Form 8-K may contain "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission.

**Item 9.01. Financial Statements and Exhibits.**

***(d) Exhibits***

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 99.1 | [Press Release](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| **MICROBOT MEDICAL INC.** | **MICROBOT MEDICAL INC.** |
| By: | */s/ Harel Gadot* |
| Name: | Harel Gadot |
| Title: | Chief Executive Officer, President and Chairman |

---

Date: November 26, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Microbot Medical<sup>®</sup> Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY<sup>®</sup> Endovascular Robotic System**

*Adoption of LIBERTY is Consistent with Emory's Commitment to the Growing and Evolving Field of Interventional Radiology*

 

**HINGHAM, Mass., November 26, 2025** — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become the first hospital to adopt LIBERTY for patient care. Additionally, Microbot is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology to enhance the growing and evolving specialty field.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. Just weeks ago, the Company commenced the limited market release of the system and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

Emory University Hospital is a leading academic medical center recognized for its excellence in patient care, research, and innovation. With the hospital's strengths in endovascular and oncology services, Microbot will support clinicians in delivering precise care for peripheral intervention procedures such as liver tumor embolization, prostate artery embolization and uterine fibroid embolization, among others.

"Introducing innovative technologies such as LIBERTY to our interventional radiology program underscores our priority to remain at the forefront of technological advancement. We anticipate that its single-use, remotely operated design will offer a practical and scalable approach to robotics that supports our operational goals, protects our clinicians and provides access to quality care," says J. David Prologo, MD, division director for Interventional Radiology, Emory University School of Medicine.

"This is an extraordinary occasion for Microbot Medical, and we believe a major milestone for the entire surgical robotic space. We are establishing a completely new medical robotic category with the adoption of the first FDA-cleared single-use robotic system. This achievement reflects years of dedication and sustained progress by the entire team," commented Harel Gadot, CEO, President & Chairman. "Emory University Hospital clinicians and researchers have demonstrated enthusiasm early on about this technology and in providing additional access to new technology for physicians and patients in the evolving field of medical robotics. We are proud to welcome them as the first adopter of LIBERTY, and we are committed to supporting them every step of the way to ensure clinical and operational success."

**About Microbot Medical**

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY<sup>®</sup> Endovascular Robotic System is the world's first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation

Learn more at <u>www.microbotmedical.com</u> and connect on <u>LinkedIn</u> and <u>X</u>.

**Safe Harbor**

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts," "intends," "may," "might," "possible," "potential," "predicts," "projects," "should," "would," "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY<sup>®</sup> Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical<sup>®</sup> can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at <u>www.sec.gov</u>. Microbot Medical<sup>®</sup> disclaims any intent or obligation to update these forward-looking statements, except as required by law.

**Contacts:**

<u>IR@microbotmedical.com</u>

<u>Media@microbotmedical.com</u>